- CEO Dr. Vuong Trieu recognized as inventor of multibillion-dollar oncology assets, including Abraxane(R) and Cynviloq(TM)
- OTLC advancing late-stage pipeline led by OT-101 in Phase 3 for pancreatic cancer and multiple other high-unmet-need indications
- Recent progress includes 2 years of steady clinical and regulatory advancements across oncology and rare pediatric programs
The biotechnology sector is defined by its ability to pair scientific innovation with leadership that can translate discoveries into approved therapies. This is particularly critical in oncology, where late-stage candidates must navigate complex regulatory pathways and demonstrate real clinical impact in indications with limited treatment options. Companies that combine robust intellectual property with seasoned leadership are positioned to accelerate value creation for patients and investors alike.
Oncotelic Therapeutics (OTCQB: OTLC) is one such example, advancing a diverse clinical pipeline under the leadership of Chairman and CEO Dr. Vuong Trieu. With a track record of developing oncology blockbusters, Dr. Trieu provides both scientific and commercial credibility as the company drives its portfolio of late-stage drug candidates toward market readiness.
A Proven Innovator in Oncology
Dr. Trieu has built a reputation as one of the industry’s most prolific innovators, with more than 500 filed patents and 75 issued patents spanning biologics, small molecules, nanoparticles, and diagnostics. He is best known for co-inventing Abraxane(R) (nab-paclitaxel), a cancer therapy acquired by Celgene in 2010 in a $2.9 billion transaction, and developing Cynviloq(TM), later sold to NantPharma in a $1.3 billion deal.
His career contributions span breast, pancreatic, and non-small cell lung cancers, as well as cardiovascular and infectious diseases, rare pediatric disorders, and immunotherapies. At Oncotelic, this expertise underpins a strategy of converting tumor-microenvironment biology into clinic-ready, globally protected therapies.
Pipeline Highlights: Targeting High-Need Indications
Oncotelic’s portfolio includes a mix of clinical-stage and discovery-stage assets targeting cancer, neurodegeneration, and rare diseases:
- OT-101 (Trabedersen): A first-in-class antisense therapeutic inhibiting TGF-β2, now in Phase 3 trials for pancreatic cancer. OT-101 has also shown promise in glioblastoma, colorectal cancer, and COVID-19-related ARDS
- OXi4503: A vascular disrupting agent in Phase 2 for acute myeloid leukemia (“AML”) and myelodysplastic syndromes (“MDS”), advancing toward pivotal Phase 3 design
- CA4P / Fosbretabulin: A late-stage oncology agent under repositioning, with rare pediatric designation in melanoma
- AL-101: An intranasal apomorphine candidate in Phase 2 for Parkinson’s disease and sexual dysfunctions, addressing multibillion-dollar global markets
- AL-102: A discovery-stage oligonucleotide antisense therapy targeting Alzheimer’s disease
This portfolio strategy balances late-stage de-risked assets with early-stage innovation, while rare pediatric programs offer potential access to U.S. FDA Priority Review Vouchers (“PRVs”).
Two Years of Clinical Progress
In September 2025, Oncotelic provided a snapshot of two years of advancement across its pipeline. Key highlights include:
- OT-101 advancing into Phase 3 for pancreatic cancer, supported by encouraging efficacy and safety signals in earlier studies
- OXi4503 showing potential in hematologic malignancies, with Phase 2 data informing pivotal trial design
- Expansion of AL-101 into both neurology and sexual health, reflecting its broad therapeutic potential
- Acceleration of nanomedicine programs through the FDA’s 505(b)(2) pathway, offering a faster and more cost-efficient regulatory route
These milestones underscore Oncotelic’s transition into a late-stage biotech with multiple value-creation opportunities.
Intellectual Property as a Strategic Moat
Beyond its clinical assets, Oncotelic benefits from the extensive IP portfolio, which strengthens competitive barriers and reinforces the company’s long-term positioning. The combination of owned and licensed programs, along with a 45% stake in joint venture GMP Bio, creates additional optionality for growth.
Dr. Trieu himself emphasized this approach: “Our strength lies not only in OTLC’s clinical pipeline but also in the breadth of intellectual property generated over my career… We remain committed to transforming these innovations into life-saving therapies for patients and long-term value for shareholders.”
Positioned for Value Creation
As biotech investors increasingly focus on companies with late-stage pipelines, clear regulatory pathways, and leadership with proven track records, Oncotelic aligns well with sector trends. Its flagship OT-101 program in pancreatic cancer addresses one of the highest unmet needs in oncology, while additional candidates in AML, Parkinson’s, and Alzheimer’s diversify risk and broaden opportunity.
With a strengthened clinical pipeline, expanding IP base, and two years of steady regulatory progress, Oncotelic is positioned to advance its mission of delivering first-in-class therapies for high-need indications while building long-term shareholder value.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
